Last reviewed · How we verify
SGX301 (synthetic hypericin)
SGX301 is a synthetic hypericin that generates reactive oxygen species upon light activation to destroy targeted cells, particularly in photodynamic therapy applications.
SGX301 is a synthetic hypericin that generates reactive oxygen species upon light activation to destroy targeted cells, particularly in photodynamic therapy applications. Used for Cutaneous T-cell lymphoma (mycosis fungoides), Other dermatologic malignancies and lesions amenable to photodynamic therapy.
At a glance
| Generic name | SGX301 (synthetic hypericin) |
|---|---|
| Also known as | Hypericin, Synthetic Hypericin |
| Sponsor | Soligenix |
| Drug class | Photosensitizer |
| Target | Hypericin (photosensitizing agent); generates ROS upon light activation |
| Modality | Small molecule |
| Therapeutic area | Oncology; Dermatology |
| Phase | Phase 3 |
Mechanism of action
Hypericin is a naturally occurring photosensitizer that, when activated by visible light, produces singlet oxygen and other reactive oxygen species that cause direct cytotoxic damage to cells. SGX301 is a synthetic formulation designed to improve the pharmacokinetic properties and therapeutic efficacy of hypericin for use in photodynamic therapy, enabling selective destruction of diseased tissue while minimizing systemic toxicity.
Approved indications
- Cutaneous T-cell lymphoma (mycosis fungoides)
- Other dermatologic malignancies and lesions amenable to photodynamic therapy
Common side effects
- Photosensitivity/phototoxicity
- Skin irritation at treatment site
- Erythema
- Pain or burning at application site
Key clinical trials
- Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light (PHASE2)
- HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL (PHASE2)
- PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma (PHASE2)
- FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SGX301 (synthetic hypericin) CI brief — competitive landscape report
- SGX301 (synthetic hypericin) updates RSS · CI watch RSS
- Soligenix portfolio CI